Table 2.
Clinical factors related to a ≥ 50% reduction in MMD at 6 months.
| <50% 6 M | ≥50% 6 M | p value | |
|---|---|---|---|
| n (M/F) | 36 (8/28) | 74 (19/55) | 0.693 |
| Migraine diagnosis, EM/CM | 5/31 | 42/32 | <0.001 |
| Fremanezumab dozing, monthly/quarterly | 23/13 | 42/32 | 0.475 |
| Age, years | 45.2 ± 10.9 | 45.6 ± 12.9 | 0.882 |
| Body mass index (kg/m2) | 22.5 ± 3.8 | 22.5 ± 3.7 | 0.973 |
| Migraine with aura, n (%) | 6 (16.7) | 18 (24.3) | 0.362 |
| Medication overuse headache, n (%) | 9 (25.0) | 8 (10.8) | 0.053 |
| Disease duration, years | 25.9 ± 10.1 | 25.9 ± 5.8 | 0.987 |
| Pain location, n (%) | |||
| Unilateral | 25 (69.4) | 45 (60.8) | 0.377 |
| Bilateral | 27 (75.0) | 52 (70.3) | 0.605 |
| Pain characteristics, n (%) | |||
| Pulsating | 31 (86.1) | 68 (91.9) | 0.343 |
| Pressing | 25 (69.4) | 46 (62.2) | 0.454 |
| Others | 1 (2.8) | 2 (2.7) | 0.982 |
| Sensory hypersensitivity, n (%) | |||
| Photophobia | 26 (72.2) | 62 (83.8) | 0.155 |
| Phonophobia | 28 (77.8) | 57 (77.0) | 0.930 |
| Osmophobia | 17 (47.2) | 37 (50.0) | 0.785 |
| Nausea | 29 (80.6) | 69 (93.2) | 0.045 |
| Allodynia | 7 (19.4) | 12 (16.2) | 0.674 |
| Number of preventive medication classes used previously, n (%) | 0.586 | ||
| 1 | 7 (19.4) | 22 (29.7) | |
| 2 | 13 (36.1) | 24 (32.4) | |
| 3 | 8 (22.2) | 19 (25.7) | |
| 4 | 4 (11.1) | 5 (6.8) | |
| ≥5 | 4 (11.1) | 4 (5.4) | |
| Baseline MMD, n (%) | 22.0 ± 5.8 | 14.4 ± 5.7 | <0.001 |
| Comorbidities, n (%) | 18 (50.0) | 40 (54.1) | 0.689 |
| ≥2, n (%) | 17 (47.2) | 33 (44.6) | 0.795 |
≥50% 6 M, ≥50% reduction in MMD at 6 months; <50% 6 M, <50% reduction in MMD at 6 months; MMD, monthly migraine days.
Significant differences in p value are indicated in bold.